Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19.
COVID-19
SARS-CoV-2
coronavirus disease 2019
fertility
oligo-crypto-azoospermia
semen
severe acute respiratory syndrome coronavirus 2
sexual transmission
Journal
Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199
Informations de publication
Date de publication:
17 05 2021
17 05 2021
Historique:
received:
08
10
2020
revised:
28
12
2020
pubmed:
2
2
2021
medline:
21
5
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
How is the semen quality of sexually active men following recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection? Twenty-five percent of the men with recent SARS-Cov-2 infections and proven healing were oligo-crypto-azoospermic, despite the absence of virus RNA in semen. The presence of SARS-CoV-2 in human semen and its role in virus contagion and semen quality after recovery from coronavirus disease 2019 (COVID-19) is still unclear. So far, studies evaluating semen quality and the occurrence of SARS-CoV-2 in semen of infected or proven recovered men are scarce and included a limited number of participants. A prospective cross-sectional study on 43 sexually active men who were known to have recovered from SARS-CoV2 was performed. Four biological fluid samples, namely saliva, pre-ejaculation urine, semen, and post-ejaculation urine, were tested for the SARS-CoV-2 genome. Female partners were retested if any specimen was found to be SARS-CoV-2 positive. Routine semen analysis and quantification of semen leukocytes and interleukin-8 (IL-8) levels were performed. Questionnaires including International Index of Erectile Function and Male Sexual Health Questionnaire Short Form were administered to all subjects. The occurrence of virus RNA was evaluated in all the biological fluids collected by RT-PCR. Semen parameters were evaluated according to the World Health Organization manual edition V. Semen IL-8 levels were evaluated by a two-step ELISA method. After recovery from COVID-19, 25% of the men studied were oligo-crypto-azoospermic. Of the 11 men with semen impairment, 8 were azoospermic and 3 were oligospermic. A total of 33 patients (76.7%) showed pathological levels of IL-8 in semen. Oligo-crypto-azoospermia was significantly related to COVID-19 severity (P < 0.001). Three patients (7%) tested positive for at least one sample (one saliva; one pre-ejaculation urine; one semen and one post-ejaculation urine), so the next day new nasopharyngeal swabs were collected. The results from these three patients and their partners were all negative for SARS-CoV-2. Although crypto-azoospermia was found in a high percentage of men who had recovered from COVID-19, clearly exceeding the percentage found in the general population, the previous semen quality of these men was unknown nor is it known whether a recovery of testicular function was occurring. The low number of enrolled patients may limit the statistical power of study. SARS-CoV-2 can be detected in saliva, urine, and semen in a small percentage of men who recovered from COVID-19. One-quarter of men who recovered from COVID-19 demonstrated oligo-crypto-azoospermia indicating that an assessment of semen quality should be recommended for men of reproductive age who are affected by COVID-19. None. N/A.
Identifiants
pubmed: 33522572
pii: 6125160
doi: 10.1093/humrep/deab026
pmc: PMC7953947
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1520-1529Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
J Endocrinol Invest. 2020 Dec;43(12):1819-1822
pubmed: 32329026
JAMA. 2020 Mar 24;323(12):1129-1130
pubmed: 32207807
J Reprod Immunol. 2013 Nov;100(1):20-9
pubmed: 23668923
Facts Views Vis Obgyn. 2009;1(1):18-26
pubmed: 25478067
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Andrology. 2021 Jan;9(1):88-98
pubmed: 32436355
JAMA Netw Open. 2020 May 1;3(5):e208292
pubmed: 32379329
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Andrology. 2017 Jul;5(4):640-663
pubmed: 28622464
Andrologia. 2020 Oct;52(9):e13712
pubmed: 32578263
Fertil Steril. 2011 Jun 30;95(8):2557-9
pubmed: 21620397
Hum Reprod. 2012 Dec;27(12):3393-402
pubmed: 23019300
Int J Androl. 2011 Dec;34(6 Pt 1):600-13
pubmed: 20969602
Cells. 2020 Apr 09;9(4):
pubmed: 32283711
J Reprod Immunol. 2013 Nov;100(1):54-65
pubmed: 23611586
Nat Rev Urol. 2015 Jul;12(7):401-13
pubmed: 26101108
J Urol. 1989 Jul;142(1):62-5
pubmed: 2499695
Semin Cell Dev Biol. 2014 Jun;30:2-13
pubmed: 24598768
Am J Reprod Immunol. 2018 Aug;80(2):e12992
pubmed: 29992660
N Engl J Med. 2018 Apr 12;378(15):1440-1441
pubmed: 29641967
Biol Reprod. 2020 Jun 23;103(1):4-6
pubmed: 32297920
J Med Virol. 2020 Sep;92(9):1676-1680
pubmed: 32330305
J R Soc Med. 2006 Nov;99(11):573-5
pubmed: 17082302
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
Fertil Steril. 1951 Nov-Dec;2(6):523-33
pubmed: 14887770
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Lancet Infect Dis. 2020 Apr;20(4):410-411
pubmed: 32087116
Eur Urol. 2007 Feb;51(2):524-33; discussion 533
pubmed: 16905241
Hum Reprod. 2003 Oct;18(10):2089-92
pubmed: 14507826
Andrology. 2021 Jan;9(1):42-47
pubmed: 32598557